Technical Articles

This article focuses on the molecular characteristics and clinical distribution of KRAS G12D as the most common KRAS mutation subtype, systematically elaborates the challenges in drug development due to the lack of covalent binding sites and unique GTP hydrolysis kinetics, and explores how TCR-T cell therapy-based immunotherapy strategies can achieve precise targeting of this "death star" using MHC-peptide tetramer technology.

The KRAS gene is one of the oncogenes frequently mutated in tumors, with the G12D mutation widely present in various malignant tumors such as pancreatic cancer, colorectal cancer, and lung cancer.

The KRAS gene is one of the most common oncogenes in human cancers, frequently mutated in various solid tumors such as pancreatic cancer, colorectal cancer, and lung cancer.